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AnnexinWe recently identiﬁed several Ca2+-binding proteins (CaBP) from the S100 and annexin family to be regulated
by TSH in FRTL-5 cells. Here, we study the regulation of S100A4, S100A6 and ANXA2 in primary human
thyrocytes (PHT) derived from surrounding tissues (ST), cold benign thyroid nodules (CTN) and autonomously
functioning thyroid nodules (AFTN). We investigated the expression and regulation of CaBP and the effect of
their expression on Ca2+ and TSHR signaling.Weused an approach that accounts for the potential of an individual
PHT culture to proliferate or to express thyroid differentiation features by assessing the expression of FOS and
TPO.We found a strong correlation between the regulation of CaBP and the proliferation-associated transcription
factor gene FOS. PKA and MEK1/2 were regulators of ANXA2 expression, while PI3-K and triiodothyronine were
additionally involved in S100 regulation. The modulated expression of CaBP was reﬂected by changes in ATP-
elicited Ca2+ signaling in PHT. S100A4 increased the ratio of subsequent Ca2+ responses and showed a Ca2+
buffering effect, while ANXA2 affected the ﬁrst Ca2+ response to ATP. Overexpression of S100A4 led to a reduced
activation of NFAT by TSH. Using S100A4 E33Q, D63N, F72Q and Y75K mutants we found that the effects of
S100A4 expression on Ca2+ signaling are mediated by protein interaction. We present evidence that TSH has
the ability to ﬁne-tune Ca2+ signals through the regulation of CaBP expression. This represents a novel putative
cross-regulating mechanism in thyrocytes that could affect thyrocyte signaling and physiology.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The pituitary hormone thyrotropin (thyroid stimulating hormone,
TSH) is the main regulator of thyroid growth and physiology. This role
is mediated by the TSH receptor (TSHR), a G-protein coupled receptor
(GPCR) which signals to numerous intracellular signaling pathways
via small heterotrimeric GTPases (G-proteins) of the classes Gs, Gq/11,
Gi/o, G12 [1] and G13 [2]. More than 20 years ago TSHR coupling to
Gsα and subsequent activation of cAMP signaling have been established
[3]. Today TSH and its receptor are still considered themain regulator of
thyroid growth and function by regulating proliferation, iodine uptake
and hormone secretion. But other growth factors (e.g. insulin-like
growth factor (IGF)-I) and signalingmolecules (e.g. purines)were iden-
tiﬁed as regulators of thyroid function and TSH signaling has become
more complex. For example, by coupling to Gq/11and Gβγ, TSH induces
a calcium release via the canonical phospholipase C β (PLCβ)-inositol
phosphate cascade [4]. This cascade can also be activated by ATPTN, autonomously functioning
rounding tissue; CaBP, calcium
sclose.
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ights reserved.signaling via P2Y receptors or receptor tyrosine kinases like the IGF
receptor [5,6].
Calcium is a regulator of various stages of thyroid hormone syn-
thesis, including H2O2 synthesis by dual oxidase activation [7], iodine
organiﬁcation bymodulating thyreoperoxidase (TPO) activity, andpino-
cytosis [8]. Furthermore, it is an important downstream regulator of
thyroid cell growth [9]. Ca2+ is also an activator of several transcription
factors like Fos or NFAT, thereby controlling proliferation and gene
expression.
S100 proteins are small (10–12 kDa) acidic proteins containing two
EF-hands and form the largest familywithin the EF-hand protein super-
family [10]. These EF-hands are high-afﬁnity Ca2+-binding motifs
which are ﬂanked by α-helices on both sides [11]. S100 proteins form
homo- and heterodimers with proteins of their own family or other,
unrelated proteins [12]. This dimerization occurs at a hydrophobic
region which is exposed after binding of Ca2+. The amino acids that
form the hydrophobic cleft deﬁne the speciﬁcity of their binding to
various partners like p53 [13], annexin A2 (ANXA2) [14] or Ndr kinase
[15]. S100 proteins are multifunctional signaling proteins involved in
numerous processes like muscle contraction, cell growth, differentia-
tion, transcriptional control and cell cycle progression. This variety of
functions is reﬂected by a speciﬁc expression pattern seen for many of
the family members.
Alterations of the expression levels of S100 proteins are associated
with tumors and their malignancy. S100A4 was found to be associated
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prometastatic properties [17]. It has been found in a variety of cancers
like colorectal, esophagus and gall bladder cancer [18]. Of special interest
is the detection of S100A4 in PTC [19,20], the follicular variant of PTC [21]
and anaplastic thyroid carcinoma [22].
We recently discovered a regulation of S100 and annexin proteins by
TSH in rat thyroid FRTL-5 cells [23]. The expression of S100 proteins
attenuates intracellular Ca2+ levels after stimulation of purinergic P2Y
receptors and leads to a buffering of Ca2+ levels. Furthermore, an ATP-
dependent induction of the transcription factor Fos was found to be
modulated by S100 overexpression.
To study Ca2+ and Ca2+-binding proteins (CaBPs) in amore physio-
logical and thyroid disease related setting, we examined the expression
of S100 and annexin proteins in primary human thyrocytes (PHT)
obtained from autonomous functioning (AFTN) and cold benign (CTN)
thyroid nodules and their surrounding tissues (ST). We examined the
impact of CaBP expression levels onATP-elicited Ca2+ signals and studied
the pathways regulating S100 and annexin expression in PHT.We further
examined the impact of S100 expression onNFAT activation by TSHR and
deﬁned the molecular components of S100 proteins involved in their
regulation of Ca2+ buffering.
2. Material and methods
2.1. Reagent suppliers
Cell culture media were purchased from PAA Laboratories, Pasching,
Austria and Invitrogen, Carlsbad, CA, USA. TSH, insulin, triiodothyronine
(T3), LY294002, GF109203X, H-89, pertussis toxin, U0126, forskolin,
wortmannin and Hanks Balanced Salt Solution (HBSS) were purchased
from Sigma Aldrich Chemie GmbH, Munich, Germany.
2.2. Cell culture
2.2.1. HEK 293 GripTite
The human embryonic kidney cell lineHEK293GripTite (Invitrogen)
was maintained in DMEM high glucose medium supplemented with
10% FCS, 0.1 mM non-essential amino acids and 600 μg/ml G418 at
37 °C and 5% CO2.
2.2.2. Preparation and culture of primary human thyrocytes (PHT)
Biopsies of thyroid tissues were taken during surgery for nodular
thyroid disease. The present studywas approvedby the Ethics Committee
of the Medical Faculty at the University of Leipzig (085-2006) and
informed consent was obtained from all patients before surgery. The
processing of tissue specimens and the preparation of follicles were
adapted from Eszlinger et al. [24]. After removal from the patient and
assessment by the clinic's pathologist, biopsies were quick-rinsed in 70%
ethanol and sterile PBS. Thyroid tissue was cut into pieces of 1 mm
diameter. The tissue fragments were incubated for 15 min with
2.4 U/ml Dispase II neutral protease (Roche, Mannheim, Germany),
at 37 °C andharvested by sieving through a 0.5 mmsteelmesh. All frac-
tions from 4 consecutive digestions of one tissue were combined and
cell and follicle numbers were estimated by light microscopy. Follicles
were seeded into culture dishes andmaintained in RPMI-1640medium
supplementedwith 1% FCS at 37 °C and 5% CO2. Cells werewashedwith
PBS after 24 h to remove remaining erythrocytes. Serum-free RPMI-
1640was added and cellsweremaintained between2 and 4 days. Stim-
ulation was performed with 1 mU bovine TSH and 10 μg/ml insulin
24 h before experiments.
2.3. RNA isolation
Total RNA was isolated from cell cultures using TRIzol reagent
(Invitrogen) according to the manufacturer's instructions. RNA con-
tent and quality was assessed by O.D. reading and by determiningthe A260/280 ratio. RNA integrity was evaluated on ethidium
bromide-stained denaturing agarose gels.
2.4. Hydrolysis probe-based reverse transcription quantitative PCR
cDNA was synthesized from 1 μg of total RNA per 30 μL reaction
volume using 200 U M-MLV reverse transcriptase (Invitrogen),
45 pmol/μg oligo-dT18 for priming and 15 U peqGOLD RNAse inhibitor
(Peqlab, Erlangen, Germany). 1 μL cDNAwas quantiﬁed on a LightCycler
480 real-time PCR 96 well thermocycler using LightCycler 480 Probes
Master Mix (Roche Diagnostics GmbH, Mannheim, Germany). Primer
and probe sequences are given in the supplement. Gene expression
was measured as multiplex assay using 5–10 pmol primer and 50–
200 pmol probe per 20 μL reaction volume. The efﬁciency of the ampli-
ﬁcation of each gene in eachmultiplex reactionwas assessed bymeasur-
ing a serial 1:4 cDNA dilution series as calibration curve using the
method by Pfafﬂ et al. [25]. The limit of quantiﬁcation was deﬁned as
the ﬁrst quantiﬁcation cycle of the calibration curve that deviated from
the regression line ΔCq/Δlog2d and whose inclusion into the regression
decreased the goodness of ﬁt R2 below 0.995. Samples giving Cq values
below the limit of quantiﬁcation were excluded from the analysis.
2.5. Cloning and mutagenesis
Cloning of S100A4 protein into pIRES-dsRed-Expres vector
(Clontech-Takara Bio Europe, Saint-Germain-en-Laye, France) was
described before [23]. S100A4 mutants were generated by site-
directed mutagenesis using the QuikChange site-directed mutagenesis
kit (Stratagene, La Jolla, CA, USA). For primer sequences please see
supplement.
2.6. Calcium imaging
For calcium imaging experiments, HEK293 GripTite cells were plated
into a 12-well plate containing glass coverslips at 2.6 × 104 cells per cm2
and grown for 24 h. Transfection was performed using GeneJammer
(Stratagene, La Jolla, CA, USA) and 1 μg S100A4-pIRES-dsRedExpress or
empty pIRES-dsRedExpress vector and cells were grown for another
48 h before imaging experiments. PHTwere cultured on glass coverslips
using the same conditions as described above. For imaging, cells were
loadedwith 1 μMFura-2 AM (Invitrogen) for 30 min at 35 °C. Measure-
ments were performed at room temperature under constant perfusion
with 1 ml/min Ca2+- and Mg2+-free NaHCO3-buffered HBSS. The cells
were stimulated by computer-controlled addition of the stimulating
agent to the perfusion ﬂow. Images were taken every 6 s with a
TillVision imaging system (Till-Photonics; Munich, Germany) equipped
with a Zeiss C-Apochromat 40× 1.2 Wwater immersion objective. Back-
ground subtraction and signal extraction were performed using the
ImageJ for Microscopy package [26]. Using a self-programmed R script
[27], the start- and endpoints of peaks were automatically detected.
For evaluated peaks, the baseline, peak height, integrated peak area,
the peak height ratio to its area, and the ratios of peak height and area
between second and ﬁrst peak were calculated. The results of multiple
measurements of the sameexperimental condition or from the same pa-
tient and condition were averaged before calculating an overall mean
and standard deviation. For the examination of S100A4 mutants,
transfected cells were identiﬁed by dsRedExpress ﬂuorescence
(exc. 560 nm, emm. 590 nm) and compared to the mean of all
untransfected cells.
2.7. Luciferase gene reporter assays
Luciferase reporter gene assayswere carried out using AP-1 andNFAT
luciferase reporter plasmids (Clontech, Saint-Germain-en-Laye, France).
HEK293 GripTite cells were plated at a density of 1 × 105 cells/cm2 in
24-well plates. Cells were transfected after 24 h with 100 ng reporter
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Dr. Jäschke, Leipzig) and 100 ng S100A4-dsRedExpress or 100 ng
dsRedExpress in pcDNA3.1(−) (Invitrogen) as control. The growth
medium was replaced 36 h post-transfection with reduced serum diet
medium (DMEM, 1% FCS, 600 μL/ml G418 and 0.1 mM NEAA). After
12 h, TSH or other signaling activators were added and the cells were
incubated for 6 h at 37 °C and 5% CO2. If inhibitors were employed, they
were added 15 min before the addition of TSH. The incubation was
stopped by washing the cells once with PBS and freezing at−18 °C for
30 min. Luciferase activity was analyzed on a Mithras LB940 multimode
reader (Berthold Technologies GmbH & Co KG, Bad Wildbad, Germany)
using the Promega Luciferase Assay system (Promega GmbH,Mannheim,
Germany) according to the manufacturer's instructions.
3. Results
3.1. Generation of primary thyroid cultures
The preparation protocol yielded primarily follicle aggregates and
very few single cells. After seeding into 1% FCS containing medium,
the follicles adhered to the culturing surface and acquired a spread
out, ﬂattened form (Fig. 1). After removal of FCS from the growth
medium, we observed no visible proliferation or change in cell mor-
phology, indicating that the cultured cells remained quiescent during
the course of the experiment.
3.2. mRNA expression proﬁling in PHT
For this study, primary cultures of 41 individuals were established.
Nodular tissue of 11 patients was excluded due to uncertain diagnosis.
This left 23 patients with clinically deﬁned CTN. From 7 patients with
AFTN, one was excluded due to a multinodular goiter with 2 AFTN and
1 CTN. Surrounding tissues (ST), i.e. healthy tissues surrounding the
nodules or from the lateral lobe, of 28 patients diagnosed with CTN or
undetermined nodules were included. The whole expression dataset
was analyzed with regard to medications the patients received before
surgery. There was no impact of the medication on any particular
gene expression parameter; therefore no patients with medications
were excluded.
The mRNA expression of the thyroid differentiation markers TSHR
and TPO, the proliferation-associated transcription factor FOS and the
CaBPs ANXA2, S100A4 and S100A6 was measured in the sample cohort
by RT-qPCR using custom designed hydrolysis probes. Neither stimula-
tion with TSH nor the type of tissue the primary culture was derived
from had an impact on the expression level of the reference gene
RPL27 (TSH untreated: n = 235, quantiﬁcation cycle (Cq) 19.09; TSH
treated: n = 238; Cq 19.20, CTN: n = 223, Cq 19.10, ST: n = 184, Cq
19.19).
The prevalence of the examined genes varies greatly (Fig. 2A).
S100A6 showed the strongest expression relative to RPL27, followed
by ANXA2, TSHR and S100A4, ranging from 22.87 to 2−4.74 copies perFig. 1. Follicular-likeﬂattened structures of PHT 36 h after seeding. Imageswere acquired during Ccopy RPL27. TPO showed a broad relative expression range from 2−2.44
to 2−15.0 with a median of 2−7.53, while the transcription factor FOS
showed the lowest prevalence of 2−11.52 copies per copy RPL27.
The relative expression of these genes was examined in TSH-treated
and untreated PHT derived from ST (n = 28), CTN (n = 23) and AFTN
(n = 6). TSHR (2B) and TPO (2C) as thyroid marker genes were signif-
icantly upregulated in all thyrocyte cultures after TSH treatment. How-
ever, unstimulated cultures of CTN and AFTN both show a decreased
basal, unstimulated expression level of TPO compared to ST. The TSH-
induced increase ofmRNA expression of TSHR and TPOwas signiﬁcantly
correlated across all thyrocyte cultures (2C).
FOS, ANXA2, S100A4 and S100A6 (2E-H) showed no signiﬁcant reg-
ulation by TSH in the different groups of PHT. Instead, the expression
levels of these genes varied between the groups of PHT. FOS and
ANXA2 were expressed signiﬁcantly higher in AFTN-derived PHT
(2.8 fold and 1.6-fold). S100A6 was downregulated in PHT derived
fromCTN (1.33-fold) and AFTN (2.5-fold), compared to ST-derived PHT.
We previously observed [23] that primary thyrocyte cultures, re-
gardless of the physiological state of their origin, vary in their ability
to remain differentiated in cell culture. We therefore considered the
TSH-mediated induction of TPO, which plays a crucial part in thyroid
hormone synthesis, as key indicator to quantify the responsiveness of
PHT cultures in regard to this central physiological process of thyrocytes.
By contrast, the TSH-induced expression of FOS, which encodes a tran-
scription factor closely associatedwith proliferation,was used as an indi-
cator for the proliferative response of PHT cultures. We then correlated
the induction of CaBP expression by TSH with either TPO (data not
shown) or FOS (Fig. 3) for each experimental group.
ANXA2 is verywell coregulatedwith FOS in all types of PHT. If the in-
dividual culture reacts to TSH by a decreased expression of FOS, ANXA2
expression is also decreased, and vice versa. S100A4 and S100A6 are
coregulated with FOS in PHT derived from ST.
Concerning the correlation of CaBP with TPO, a slight correlation
between TPO and S100A4 expression in ST-derived PHT (r = 0.44,
p = 0.04) was found. ANXA2 slightly missed a signiﬁcance of corre-
lation with TPO, while S100A6 showed no coregulation at all.
The mRNA expression of all three CaBP was veriﬁed at the protein
level usingWestern blotting for S100A4, S100A6 andANXA2 on a repre-
sentative subset of samples. The mRNA and protein levels correlated
well (ANXA2: r = 0.899**, S100A4: r = 0.804**, S100A6: r = 0.780*).
Please see Supplementary Fig. 1 for more details.3.3. Signaling pathways involved in the regulation of calcium
binding proteins
To study the signaling pathways involved in the regulation of CaBP
expression, several thyroid-relevant signaling pathwayswere examined
(Fig. 4A–C). Inhibition of PKA with H-89 and MEK1/2 with U0126
reduced the expression of all three examined proteins to an extent of
approximately 40–70%. Inhibition of PI3-K by LY294002 and PKC by
GF109203X reduced the expression of S100A4 and S100A6 by 30 toa2+-imaging experiments and showPHT, loadedwith 1 μMFura-2AMat resting Ca2+ levels.
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treated cultures. Since TSH itself had no effect, the datasets of TSH-
treated and untreated PHT were combined. Furthermore, pertussis
toxin showed no effect, eliminating an involvement of Gi proteins in
the regulation of these genes.
Stimulation of PHT cultures with the adenylate cyclase activator
forskolin (Fig. 4D) showed effects that are similar to TSH, i.e. a strong
upregulation of TPO and downregulation of the expression of ANXA2,
S100A4 and S100A6.
3.4. Regulation of S100A4 and S100A6 by T3
Primary thyroid cultures from 4 patients were treated with different
concentrations of Triiodothyronine (T3) for 48 h before 1 mU TSH was
added for another 24 h (Fig. 5). S100A4 expression signiﬁcantly de-
creased at low T3 concentrations and gradually increased with rising
T3 concentrations, reaching signiﬁcance at 14.3 pmol/l T3. S100A6expression signiﬁcantly increased to its maximum expression level at
14.2 pmol/l T3. T3 did not modulate the effect of TSH on S100A4 and
S100A6 expression (data not shown).3.5. Ca2+ signaling in primary human thyrocytes
To assess the physiological Ca2+ signaling in human thyrocytes and
its modulation in nodular disease, PHT were pretreated with 1 mU TSH
for 24 h and Ca2+ responses to repeated stimulation with 100 μM ATP
were recorded using Fura-2 AM ratiometric imaging in TSH-treated
and untreated control cells (Fig. 6). During initial experiments, TSH-
untreated PHT were perfused with 10 mU TSH in HBSS and Ca2+ re-
sponses were recorded accordingly (Fig. 6A). When stimulated with
TSH, cells showed very heterogeneous Ca2+ responses with high vari-
ances in response height, response initiation and duration, which sug-
gests an indirect and multicomponent signal processing. ATP induced
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We examined the Ca2+ proﬁles of PHT from ST, CTN and AFTN with
andwithout treatmentwith 1 mUTSH for 24 h in response to a repeated
stimulation with 100 μM ATP. We obtained baseline, response height,
area under the curve and the ratio of area to response height for each in-
dividual Ca2+ trace (see Supplementary Fig. 2 for explanatory details).n
o
rm
al
iz
ed
ex
pr
es
sio
n
0
20
40
60
80
100
120
* **
n
o
rm
al
iz
ed
ex
pr
es
sio
n
0
20
40
60
80
100
120
***
***
***
**
K GFX H89 LY PTX U0126
ctrl GFX H89 LY PTX U0126
A N XA 2
S100A6
A
C
Fig. 4. Examination of signaling pathways involved in CaBP gene expression. PHT from 5 patient
(PTX) or U0126. The expression of ANXA2 (A), S100A4 (B) and S100A6 mRNA (C) relative to R
cells of each culture. (D) Cultures from 8 patients were treated with 20 μM forskolin (black bar
RT-qPCR. Values are normalized to unstimulated controls (white) for each individual gene and
using one way ANOVA and Dunnett's post-test to calculate individual multiplicity-adjusted sigThe baseline Ca2+ levels before treatment indicate the amount of free
cytosolic Ca2+ in the cells. The absolute height of a Ca2+ response and
the area under the curve of a Ca2+ response are a measure of the inten-
sity and duration of a Ca2+ signal. A decrease of the ratio of the response
area to its height indicates that a CaBP modulates a Ca2+ signal by in-
creasing the response height while decreasing the duration of a signal
(lower ratio) or vice versa. We further calculated the ratio of alln
o
rm
al
iz
ed
ex
pr
es
sio
n
FO
S
TP
O
A
N
X
A
2
S1
00
A
4
S1
00
A
6
0.125
0.25
0.5
1
2
4
8
16
ctrl
TSH
For
*
***
* ** **
n
o
rm
al
iz
ed
ex
pr
es
sio
n
ctrl GFX H89 LY PTX U0126
0
20
40
60
80
100
120
***
***
***
**
S100A4
e   ects of Forskolin
B
D
s were treatedwith the inhibitors GF109203X (GFX), H-89, LY294002 (LY), pertussis toxin
PL27A was measured using RT-qPCR and normalized to the expression level of untreated
s) or 1 mU TSH (gray) for 24 h and the expression of the indicated genes measured using
culture. Statistical comparison was performed between control and inhibitor-treated cells
niﬁcances. p b 0.05, **p b 0.01, ***p b 0.001.
S100A4
S100A6
fo
ld
-
ch
an
ge
0.0
0.5
1.0
1.5
2.0
*
**
fT3 [pM]
fo
ld
-
ch
an
ge
0 1.4 4.3 14.2
0 1.4 4.3 14.2
0.0
0.5
1.0
1.5
*
fT3 [pM]
A
B
Fig. 5. Regulation of S100 calcium binding proteins by T3 in primary thyrocyte cultures.
Primary thyroid cultures from 4 different patients were stimulated with 1.4, 4.3 and
14.3 pMT3 for 48 h. The expression values for (A) S100A4 and (B) S100A6 are normalized
to untreated cells (white bars). Statistical comparison was performed using one-way
ANOVA with Dunnett's post-test and multiplicity adjustment. *p b 0.05, ***p b 0.001.
TSH 10 mU ATP 100 µMA B
time [min]
0 2 4 6 0 5 10 15 20
Fig. 6.Complex single cell Ca2+ responses to TSH versusmore uniform responses to ATP in
PHT. PHT were subjected to perfusion with (A) 10 mU TSH for 2 min, indicated by the
black bar on top, or (B) 100 μM ATP for 2× 1 min at the time points indicated by arrows
(1 and 16 min). The traces show the response proﬁles of all individual cells from a represen-
tative experiment using TSH-untreated ST-PHT of the same patient. The black bars on the
lower left depict a Fura-2 AM 340/380 nm ratio of 1. The complexity of the Ca2+ response
to TSH suggests an indirect andmulticomponent signal processing. By contrast, ATP induces
very strong and uniform responses of all cells.
ratio area 2nd/1st Ca2+ response
ra
tio
0.0
0.2
0.4
0.6
0.8
1.0
*
area/height 1 st Ca2+ response
ra
tio
0
10
20
30
40
**
area/height 2 nd Ca2+ response
ra
tio
0
10
20
30
*
ST CTN AFTN
ST CTN AFTN
ST CTN AFTN
A
B
C
ctrl TSH
Fig. 7. TSH-modulated Ca2+ response parameters grouped by origin of PHT culture. PHT
from 19 ST, 24 CTN and 3 AFTNwere stimulated for 24 h with 1 mU TSH. Ca2+ responses
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was calculated for both Ca2+ responses. All graphs show mean + SEM, within-group-
comparison was calculated using paired two-tailed t-test. *p b 0.05, **p b 0.01.
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ization.We found that the ratio of the area under the curve of both Ca2+
responses was signiﬁcantly increased after TSH treatment in PHT de-
rived from ST, but not CTN or AFTN (Fig. 7A). The ratio of the response
area to the height of the 1st Ca2+ response was signiﬁcantly reduced
in ST-PHT (Fig. 7B). PHT derived from CTN instead showed a signiﬁcant
reduction of the ratio of the response area to response height for the 2nd
Ca2+ response (Fig. 7C).
3.6. Inﬂuence of CaBP expression on Ca2+ signaling
To assess whether PHT show the same association between Ca2+
signaling and CaBP expression like FRTL-5 cells [23], robust correlation
analysis was carried out for all 25 PHT cultureswhere complete datasets
for Ca2+ imaging and gene expressionwere available, irrespective of the
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ulated with TSH or not (Table 1). This approach seemed feasible based
on the assumption that the (patho-) physiological state of the tissue
has a paramount impact on CaBP gene expression or other signaling
pathways and that altered Ca2+ signaling properties are due to those
differences.
Data showed a distinct correlation pattern between the expression
of a speciﬁc CaBP and the Ca2+ response. ANXA2 expression was in-
versely correlated with the height, the area and the area-to-height
ratio of the ﬁrst Ca2+ response. S100A4 expression was signiﬁcantly in-
versely correlated with the baseline of the ﬁrst Ca2+ response. Other-
wise it showed a strong correlation with the height and the integrated
Ca2+ response (area under curve), which is comparable to our previ-
ously observed effect in FRTL-5 cells. S100A6, which was far stronger
expressed than S100A4, showed no signiﬁcant correlations with both
Ca2+ responses.3.7. TSHR-mediated activation of NFAT and AP-1 transcription factors
Since PHT cannot be reliably transfected with high efﬁciency, we
used TSHR-overexpressingHEK293GripTite cells to study the induction
of the Ca2+-release dependent transcription factors AP-1 and NFAT
with luciferase reporter assays (Fig. 8). Both NFAT and AP-1 can be acti-
vated by TSH in TSHR-transfectedHEK293 cells. Themaximum response
was measured at 300 mU TSH for both transcription factors. The EC50
value of NFAT-stimulation with TSH (Fig. 8A) was 0.023 U TSH
(95% CI: 0.016 to 0.032). This value was right-shifted after over-
expression of S100A4 to an EC50 of 0.049 (95% CI 0.036 to 0.065) with-
out affecting themaximum response height. Activation of AP-1 (Fig. 8B)
occurred at higher concentrations than NFAT activation, with an EC50
value of 0.045 U TSH (95% CI 0.026 to 0.077) and was unaffected by
S100A4 overexpression (EC50 0.041, 95% CI 0.025 to 0.066).
To study which pathways are involved in the activation of NFAT and
AP-1 in our cell model we used several signaling activators and inhibi-
tors (Fig. 8C–D). Both transcription factorswere activated by stimulation
with 100 mU TSH. They were also activated by phorbol-12-myristate-
13-acetate (PMA, 10 ng/ml), a PKC activator. NFAT was only partially
activated, while AP-1 reached almost the same level of stimulation we
observed under TSH treatment. NFAT, but not AP-1, was also partially
activated by 1 μM ionomycin, a Ca2+ ionophore, and 20 μM forskolin,
an adenylate cyclase activator. Both transcription factors reached amax-
imal stimulation using a combination of 1 μM ionomycin and 10 ng/mL
PMA, whereby AP-1 was activated about 2.5-fold higher than with TSH.
To delineate the components that participate in the transduction of
the TSHR signal to the transcription factors NFAT andAP-1,we incubated
TSHR-overexpressingHEK293GripTite cellswith a collection of signaling
inhibitors for 15 min before adding 100 mU TSH (Fig. 8D). Signaling of
the TSH-activated TSHR to NFAT was 2-fold reduced by 100 ng/mL per-
tussis toxin (PTX), an inhibitor of Gi protein signaling. Signaling to AP-1
was not affected by PTX. The PKC inhibitor GF109203X (GFX, 5 μM) and
U0126, aMAPK/ERK kinase 1/2 inhibitor (MEK1/2, 10 μM), both reducedTable 1
Correlation of Ca2+ signaling parameters with gene expression of calcium binding proteins and
dicated on the left and the calcium signaling parameters was calculated using robust correlation
plete datasets, irrespective of the tissue the thyrocyteswere derived from. Bold numbers indicat
1st Ca2+ response
Baseline Height Area Area/heig
ANXA2 −0.145 −0.291⁎ −0.299⁎ −0.244#
S100A4 −0.277⁎ −0.001 0.087 0.047
S100A6 −0.105 0.120 −0.082 0.047
# p b 0.1.
⁎ p b 0.05.the activation of NFAT and AP-1 3.2 to 3.7-fold. The combination of
10 μM LY294002 and 1 μM wortmannin, both inhibitors of PI3-K, were
less effective and inhibited NFAT activation 2.7-fold and AP-1 activation
1.6-fold.
3.8. Properties of S100A4 mutants deﬁcient in Ca2+- and protein binding
To address thequestionwhether the effects of S100A4 expression on
Ca2+ signaling are simply due to overexpression of a Ca2+-binding
motif, i.e. the EF-hand of S100A4 protein, or are the result of an interac-
tion between S100A4 and other cytosolic components, 4 mutant
S100A4 proteins were generated. The mutants carry amino acid substi-
tutions in either one of the EF-hands that partially (E33Q) or completely
(D63N) [28] abolish Ca2+ binding or lead to the disruption of the S100
dimerization interface (F72Q, Y75K) [28,29]. The consequence of the
substitutions was studied in HEK293 GripTite cells transfected with
mutant S100A4 in the pIRES-dsRedExpress vector in order to enable
an estimation of the extent of overexpression and selection of positively
transfected cells during analysis.
Fig. 9 shows the ratio of the calcium responses after repeated stimu-
lation with 100 μM ATP. Each amino acid substitution, regardless of its
position in themolecule, abolished the effect of S100A4 overexpression.
Furthermore, overexpression of S100A4 in HEK293 cells led to a de-
crease of the calcium response ratio, in contrast to the previously re-
ported effect observed in FRTL-5 cells.
4. Discussion
In our study we examined the expression of ANXA2, S100A4 and
S100A6 in primary human thyrocytes (PHT) and their regulation by
TSH. We further examined which signaling pathways are involved in
their regulation and how modulated CaBP expression could modify
purinergic Ca2+ signaling in PHT. By using HEK293 cells we demon-
strate that CaBP expression in turn inﬂuences TSHR signaling to the
NFAT transcription factor and that the observed biological effects of
CaBP expression depend on their ability to interact with other proteins.
The regulation of CaBP is more complex in PHT than in rat thyroid
FRTL-5 cells which we used in an earlier study [23] demonstrating for
the ﬁrst time a regulation of S100 and annexin CaBP by TSH. PHT vary
in their ability to differentiate in culture, probably due to a number of
methodological (e.g. sampling, purity and culture conditions) or un-
known biological factors despite a tight control of technical variables.
FOS protein is part of the transcription factor AP-1which is activated
by TSH in a Ca2+-dependent manner and is known to take part in pro-
liferation control of normal and cancer cells [30]. TPO plays a crucial role
in thyroid hormogenesis by oxidating and coupling iodine to thyroid
hormone precursors. TPO is exclusively regulated by cAMP-dependent
TSH signaling and is often recognized as marker for well differentiated
thyrocytes. The group-wise comparison of CaBP expression in PHT
from ST, CTN and AFTN is hampered by the heterogeneity of different
cultures. By correlating CaBP expression with FOS and TPO expressiondifferentiation markers. The correlation between mRNA gene expression of the genes in-
. The analysis included the data shown in Figs. 1 and 6 of PHT from 25 samples with com-
e signiﬁcant positive correlations; italic numbers indicate signiﬁcant negative correlations.
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2710 S. Lorenz et al. / Biochimica et Biophysica Acta 1833 (2013) 2703–2713we intend to assess whether the regulation of a certain CaBP is part of a
proliferative TSH response, i.e. linked to FOS expression, or part of a re-
sponse related to thyroid function (i.e. hormone synthesis), inferred
from TPO expression.
Using this approachwe found that CaBP expression ismore correlated
with thyroid responses very likely leading to proliferation. This is further
supported by our data showing an involvement of PI3-K, PKC andMEK1/2
signaling in the regulation of the CaBP transcripts. These kinases are33 63 72 75
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Fig. 9. EF-hand and dimerization interface mutants of S100A4 lose the ability to modulate
Ca2+ signals. HEK293 GripTite cells were transfected with mutant S100A4-pIRES-
dsRedExpress constructs and the Ca2+ responses to 100 μMATPweremeasured as before.
The graph shows the mean + SEM of the ratio of the two calcium responses obtained for
untransfected control cells (white), determined by negative dsRedExpress staining, wt
S100A4 (gray) and the 4mutant proteins (dark gray). All measurements were performed
in triplicate for at least 20 positively stained cells permeasurement. *p b 0.05, determined
by ANOVA and Dunnett's multiple comparison post-test.involved in proliferative signaling in thyrocytes [31] and affected in
thyroid cancer. Nonetheless cAMP signaling seems to take part in the reg-
ulation of CaBP since PKA inhibition also inhibited CaBP expression. Since
chemical activationof PKAalso induced adownregulation of CaBP expres-
sion we conclude that cAMP signaling alone is not the main regulator of
CaBP expression.
Our data in TSHR-overexpressingHEK293 cells showed an activation
of both AP-1 and NFAT by TSH that was mimicked by Ca2+ release and
PKC activation. The activation of both transcription factors by TSH
depends on PI3-K, PKC and MEK1/2. These ﬁndings implicate that the
activation of AP-1 and NFAT by the TSHR is mediated by Gβγ and Gq
proteins that both contribute to PKC, PI3-K and MAPK signaling, which
in turn also modulate CaBP expression.
However, we could not clearly demonstrate a dependency of CaBP
expression on TSH signaling alone. Whether this is due to the small
sample size or to other factors modulating TSH signaling remains to
be elucidated.
Several mechanisms controlling S100A4 expression have been de-
scribed. The transcription factors AP-1, CBF and Sp1 are known to en-
hance S100A4 expression [32]. Most interestingly, S100A4 is regulated
by c-Fos [33] as part of an epithelial–mesenchymal transition in adeno-
carcinoma MT1TC1 cells. Our data suggest a mechanism that regulates
S100A4 expression in PHT. We show that the TSHR is able to activate
the c-Fos/AP-1 transcription factor. Further, we found a strong correla-
tion of S100A4 and also S100A6 with FOS expression. Lastly, the same
factors that inhibited AP-1 activation also reduced S100A4 expression
in this study. This allows the conclusion that S100A4 is regulated by
the AP-1 transcription factor in PHT.
The epithelial–mesenchymal transition is also found in the invading
front of PTC, in which S100A4 has been identiﬁed as an early marker
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siveness and metastatic potential of this kind of thyroid cancer [20] as
well as the formation of neoplasias [35]. S100A4 has been proposed as
a marker to discriminate between FA and the follicular variant of PTC
[21] and between PTC and FTC [36]. This indicates a function of
S100A4 in thyroid tumorigenesis. In that study, S100A4 was not differ-
entially expressed between PHT derived from ST and CTN. So if S100A4
expression has some role in tumor dedifferentiation, our data further
suggests that CTN are more close to normal than many thyroid cancer
pathologies in which aberrant expression is most likely elicited by pro-
moter hypomethylation [37].
S100A6 showed a regulation quite similar to S100A4 in PHT. In
healthy PHT, it was correlated with the degree of FOS expression. This
ﬁnding is supported by studies showing regulation of S100A6 by
PMA-activated PKC [38]. We were able to demonstrate this impact of
PKC on S100A6 expression in PHT as well.
S100A6 upregulation,mediated by the antioxidant response element
(ARE) upon stimulation with oxidative agents [39], provides a link of
S100A6 expression to thyroid physiology. During thyroid hormone syn-
thesis dual oxidases synthesize extracellular H2O2 [7]. This might trigger
ARE-mediated transcription of S100A6 [40] and could explain why
S100A6 was the highest expressed CaBP in PHT. Very interesting in
this context is a study showing that S100A6 binds to p53 and renders
HEp-2 cells more susceptible to undergo apoptosis when confronted
with H2O2 [41]. Thismay also be a relevantmechanism in PHT to control
proliferation under oxidative stress conditions.
S100A6 is associatedwith thyroid cancer too. The proteinwas found
to be upregulated in FTC and PTC [42] by immunohistochemistry.
Another study also identiﬁed S100A6 to be upregulated in FTC and
PTC andwas able to demonstrate that this is unrelated to BRAFmutations
frequently found in PTC [43].
ANXA2 regulation in PHT seems to be more directly associated with
TSHR-mediated cAMP signaling in PHT. ANXA2 was greatly suppressed
by PKA inhibition and activation. Analysis of conserved transcription
factor binding sites and ChIP-Seq data available at the UCSC Genome
Browser [44] further support a role of PKA in the regulation of ANXA2,
since p300 and C/EBPβ transcription factor binding sites are situated
in the promoter region of the ANXA2 gene. The P300 gene is a transcrip-
tional co-activator of the cAMP responsive element CREB that is a major
cAMP-dependent transcription factor in the thyroid [45]. C/EBPβ is a
transcription factor known to be regulated by TSH and insulin [46]
and is also an activator of FOS expression [47,48]. In mice, C/EBPβ
activation of FOS depends on the coactivator p300 [49]. This may ex-
plain the good correlation between FOS and ANXA2 induction in TSH-
treated PHT. Further support comes from our observation that ANXA2
expression correlated well with FOS in PHT derived from AFTN, which
are predominantly characterized by constitutive cAMP signaling.
Genes from the annexin and S100 family are related not only by
sharing the EF-hand as a common structural component. Protein inter-
actions of annexins and S100 proteins have been described several
times, for example between ANXA1 and S100A6 or S100A11 [50] and
between S100A10 and ANXA2 during membrane repair [51]. A speciﬁc
interaction exists also between S100A4 and ANXA2during angiogenesis
[52] and ANXA2 and S100A6 in pancreatic cancer cells [53], linking all
three proteins in various pathological conditions. The deleterious effects
attributed to these genes often arise from combinations of these family
members.
In our study on PHT, all three genes were coregulated with FOS ex-
pression, indicating that c-Fos is a regulator of S100A4, S100A6 and
ANXA2. We observed that the regulation of FOS and CaBP expression
upon TSH stimulation is not consistent, whichmay bedue to genetic dif-
ferences between individuals or in the specimens coming from tumor or
normal surrounding tissue. Moreover, so far unknown methodological
factors might cause heterogeneity and affect regulation of gene expres-
sion. For S100 proteins it has been shown before that their regulation in
different samples from the same tissue is often heterogeneous [54].All studied CaBP expression could be suppressed by individual stimuli
that either inhibit (Fig. 4A–C, H89) or activate PKA signaling (Fig. 4D,
Forskolin) while TSH does not show any effect (Fig. 4D, TSH). Moreover,
inhibitors of other signaling cascades also suppress ANXA2, S100A4 and
S100A6which suggests a very complex regulation. Especially the correla-
tion between CaBP (most prominent ANXA2) expression and the expres-
sion of the Ca2+-dependent transcription factor FOS very likely suggests
that the physiological status of an individual PHT culture deﬁnes its reg-
ulatory potential and not only PKA signaling but also Gq/Ca2+ signaling
seems to be involved. Therefore, the comparison of isolated stimuli
(e.g. Forskolin, H89) with TSH might only present isolated aspects. We
hypothesize that TSH signaling via PKA has basic regulatory function
for CaBP that is modulated by other signaling pathways activated by
TSH, which cannot be mimicked using forskolin alone. Chemical inhibi-
tion or activation often is not kinase isoform speciﬁc, whereas it has
been shown that TSH signaling involves at least 2 different PKA sub-
types with different properties [55]. The novel ﬁnding that S100A4
and S100A6 expression is upregulated by T3 strengthens the hypothesis
that these genes are important in thyroid physiology, worth to be ex-
plored in more detail.
The ability of TSH to trigger a Ca2+ response seems to depend very
much on the cell system and culturing condition [56,57]. In our hands,
10 mU TSH was sufﬁcient to induce a very heterogeneous Ca2+ signal
in a majority of the examined PHT, in contrast to previously reported
data [4]. However, current limitations do not allow studying the impact
of CaBP expression in PHT by overexpression or knockdown, since
those cells cannot be transfected with high efﬁciency without losing
their differentiated phenotype. Therefore we studied Ca2+-dependent
activation of AP-1 and NFAT transcription factors in HEK293 cells
overexpressing TSHR. In this cellular system, the activation of NFAT and
AP-1 was mediated by Gαq, Gαi and downstream PKC, PI3-K and
MEK1/2 signaling. S100A4 reduced the activation of NFAT while not af-
fecting AP-1, which is a coactivator of NFAT. We therefore conclude that
S100A4 interferes with TSHR signaling upstream of NFAT activation,
probably by interacting with calmodulin or calcineurin [58].
Our recent work [23] demonstrated that TSH pre-stimulation atten-
uates Ca2+ signals elicited by ATP via the P2Y receptor in FRTL-5 cells.
This attenuation is in part attributed to TSH-mediated S100A4
overexpression, while the knock-down of this protein in FTC133 leads
to a recovery of Ca2+ signals. The effect of TSH on ATP-induced Ca2+ re-
sponses was less clear in PHT. TSH had no impact on the height of Ca2+
responses, indicating a different mechanism of TSH action on Ca2+ sig-
naling in human cells compared to a rat cell line. Instead, we observed a
modulation of the integrated Ca2+ signal and the relation of the 1st in-
tegrated Ca2+ response to its height in PHT derived from ST. CTN-PHT
showed a different effect of TSH on the relation of the 2nd integrated
Ca2+ response to its height.
Since this analysis is likely aswell hampered by sample heterogeneity,
we analyzed whether the expression of CaBPs correlates with the mea-
sured Ca2+ response parameters. We found that ANXA2 is inversely cor-
related with the height, area and area-to-height ratio of the ﬁrst Ca2+
response and the baseline Ca2+ level after the 1st response, proposing
that ANXA2 reduces the ﬁrst Ca2+ response either by Ca2+ buffering or
by interacting with intracellular effectors. S100A4 expression correlated
positively with the height and area of the 2nd Ca2+ response as well as
the baseline Ca2+ level before stimulation with ATP. This ﬁnding corre-
spondswell to our previously described effects of S100A4 overexpression
in FRTL-5 rat thyrocytes, where the protein increased the 2nd Ca2+
response while reducing the 1st response. In PHT there seems a different
mechanism at work which requires two CaBP tomediate themodulation
of ATP-induced Ca2+ responses by TSH. S100A4 and ANXA2 have been
shown to interact with each other [50], suggesting an interaction-
dependent mechanism that allows both proteins to cooperate in the
modulation of Ca2+ signal transduction in PHT.
To address whether S100A4 acts on Ca2+ signaling solely by the in-
creased presence of Ca2+-binding EF-hands or by interactionwith other
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tions of the S100A4 EF-hand, which render this protein incapable of
binding Ca2+, or mutations in its dimerization interface, which abolish
interactions with other proteins, completely reversed the effect of
S100A4 overexpression in HEK293 cells. However, the mode of action
of Ca2+ binding to S100A4 is complex: binding of Ca2+ may occur at
both EF-hands and no cooperativity was found between both motifs
[59]. Ca2+ binding to the EF-hands induces a change in protein confor-
mation, making the dimerization interface accessible to interaction
partners [28]. In our work the mutation of the dimerization interface
alone was sufﬁcient to abolish S100A4's effects on Ca2+ signaling.
These mutants are still able to bind calcium, although to a lesser extent
[29]. This justiﬁes the conclusion that the binding of Ca2+ to S100A4
alone is insufﬁcient to yield a Ca2+ buffering effect.
Therefore, S100A4's effects must be mediated further downstream
of Ca2+ binding. Instead of a direct interference with Ca2+ ﬂuxes,
S100A4 could inﬂuence signaling by binding and modulating other
Ca2+-signaling proteins. A competition of several CaBP for free Ca2+
seems also possible because of structural and functional similarities in
the calmodulin superfamily [60].
Overexpression of the CaBP S100A4 and the subsequent attenuation
of intracellular Ca2+ signals lead to a reduced stimulation of Fos expres-
sion in our recent work and demonstrates how CaBP expression could
affect central cell signaling pathways. Here we show the ability of
S100A4 tomodulate the signaling of TSHR to the Ca2+-dependent tran-
scription factor NFAT [58], which is activated by dephosphorylation of
calcineurin, a protein featuring 4 EF-hands that is further regulated by
calmodulin.
Taken together, this work presents strong evidence that TSH has the
ability to ﬁne-tune Ca2+ signals elicited by GPCRs in part through the
regulation of CaBP expression. That modulation is most likely based on
complex interactions of these CaBP and not only due to their Ca2+-
binding capabilities. This represents a novel putative cross-regulating
mechanism in thyrocytes that could affect the feedback loop to TSH/
cAMP signaling via activated calmodulin-dependent phosphodiesterase,
or inﬂuence thyroid physiology in terms of H2O2 production.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.07.014.
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